Generic semaglutide recall in Canada costs its maker 710 million rupees

A generic semaglutide recall in Canada now has a figure attached. In quarterly results approved on 23 October, Dr. Reddy's Laboratories booked 710 million rupees against revenue for expected returns after it pulled batches of its semaglutide injection in August, citing an impurity above the approved limit and a separate labelling error. That comes on top of a provision of 2,397 million rupees taken in the June quarter for batches that failed specification because of a problem with the active ingredient. The company launched the product in Canada only in May.

What Health Canada posted in August

Health Canada published two Type II recall notices for semaglutide injection from Dr. Reddy's Laboratories Canada, based in Mississauga. The first, posted on 12 August, covered one lot of one product in which the pen inside the box did not match the strength printed on the label, a packaging error. The second, posted on 27 August, covered all lots of two products, eight lots in total, because an impurity was out of specification. The Health Canada impurity notice tells patients to talk to a healthcare provider before they stop using an affected product, to check whether their lot is listed, and to report side effects to the regulator. Neither notice describes any reported harm.

The timing matters because the product was new. According to a company release filed with the US Securities and Exchange Commission, Health Canada issued a Notice of Compliance on 28 April 2026, and Dr. Reddy's launched the injection on 15 May for the once weekly treatment of adults with type 2 diabetes. The company said it was the first to receive Health Canada approval for a generic semaglutide injection. The impurity recall therefore came about three months after launch. Semaglutide itself is an approved GLP-1 receptor agonist with a long safety record under its original maker, and it appears with the other incretin class molecules on our site.

How the generic semaglutide recall hit the accounts

The unaudited results for the quarter to 30 September show consolidated revenue of 86,708 million rupees, against 88,051 million a year earlier, a fall of about 1.5 percent. Profit for the period was 9,134 million rupees, against 14,268 million, a fall of about 36 percent. Note 2 of the accounts records the Canadian recall: 710 million rupees for expected product returns, taken as a reduction of revenue in the Global Generics segment. Note 5 repeats the earlier charge: in the quarter to 30 June, some semaglutide batches were found out of specification because of an issue with the active pharmaceutical ingredient, and the company provided 2,230 million rupees for inventory and 167 million for other costs.

The filing does not say how much of the fall in profit came from semaglutide, so the recall cannot be blamed for all of it.

The filing does not say how much of the fall in profit came from semaglutide, so the recall cannot be blamed for all of it. Trade Brains, an Indian markets site, attributed most of the drop in North American revenue to lower sales of lenalidomide, a cancer generic. It also reported that management expects semaglutide supply to resume in November 2026 if validation goes well, after shifting part of production to another manufacturing partner. Those statements are attributed to the company by Trade Brains and do not appear in the financial statements we read. What the accounts do show is that two separate quality problems with the same molecule landed in consecutive quarters.

Why an impurity problem matters for a peptide generic

Peptide medicines are made in many chemical steps, and each batch carries small amounts of related substances formed during synthesis or storage. Regulators set a limit for each one, and a batch above its limit cannot be released. The Canadian notes say the problem was an unspecified impurity, meaning one that is not individually named in the product specification, exceeding the approved limit. Dr. Reddy's accounts tie the June quarter charge to the active pharmaceutical ingredient and say the Canadian labelling error was unrelated to it. A generic peptide maker has to show that its impurity profile matches the reference product closely, so a lapse here goes to the core of what makes a generic acceptable.

For patients, the practical message from Health Canada is to check the lot and talk to a prescriber or pharmacist before stopping, not to switch to unregulated sources. Compounded or gray market semaglutide carries far greater uncertainty about content and purity than a recalled licensed product, which at least has a traceable lot number and a responsible company. We never name sellers, and we do not cover prices for products outside approved channels. The recall concerns one maker's lots of one product; it says nothing about semaglutide as a molecule. Readers can find our approach to quality and safety stories on our method page, which sets out how we grade each event.

What the setback means for the molecule

On our board, semaglutide stays in the approved column. This is a rebuff for one generic version, not a safety finding about the active substance, so the signal is down for the Dr. Reddy's product and the stage does not change. The episode does show how hard the first wave of peptide generics can be. Semaglutide is a modified peptide made at large scale, and the first generic makers to enter markets such as Canada carry the burden of proving consistent quality from the outset. Two charges in two quarters suggest that the company has not yet reached that point for this product, and Health Canada lists no completed corrective action on the notices we read.

The next checkpoints are concrete. Health Canada may update or close the recall notices, and any new lot approvals would be the first sign of supply returning. The company's next quarterly report will show whether more returns or provisions are needed, and whether the November supply target reported by Trade Brains held. Regulators in other markets where Dr. Reddy's sells semaglutide may also act, though none has said so in the documents we checked. Until then, the generic semaglutide recall is a reminder that a patent expiry opens a market only to products that meet the same quality bar as the original, batch after batch, in every country.

Conclusion

The generic semaglutide recall in Canada cost Dr. Reddy's 710 million rupees in expected returns last quarter, after a 2,397 million rupee charge for out of specification batches the quarter before. Health Canada advises patients to check their lot and speak to a prescriber before stopping. The molecule remains approved; the next checkpoint is whether supply resumes and the recall notices are closed.